Effects of Semaglutide on Diabetes and Weight Loss in People with Spinal Cord Injury
Glycemic and Weight Loss Effects of Semaglutide in Subjects After Spinal Cord Injury and Type 2 Diabetes
This study is looking at how well semaglutide, a medication that helps with blood sugar control and weight loss, works for people with spinal cord injuries who also have type 2 diabetes, to see if it can help them manage their diabetes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11179324 on NIH RePORTER |
What this research studies
This research investigates how semaglutide, a medication that helps control blood sugar and promote weight loss, can benefit individuals with spinal cord injuries who also have type 2 diabetes. The study aims to understand the effectiveness and safety of this treatment in a population that experiences diabetes at a higher rate than those without spinal injuries. By focusing on this specific group, the research seeks to address health disparities and improve diabetes management strategies. Participants will receive semaglutide and be monitored for changes in their blood sugar levels and weight over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with spinal cord injuries who have been diagnosed with type 2 diabetes.
Not a fit: Patients without spinal cord injuries or those who do not have type 2 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diabetes management and weight loss for patients with spinal cord injuries.
How similar studies have performed: Previous research has shown that GLP-1 receptor agonists like semaglutide are effective in managing diabetes in the general population, but this specific application in spinal cord injury patients is novel.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Salehi, Marzieh — University of Texas Hlth Science Center
- Study coordinator: Salehi, Marzieh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.